ERBB2 and breast carcinoma: As a result of further investigation in this area, there is also potential for identification of relevant downstream gene and protein biomarkers in familial breast cancers, and increased use of utility of these biomarkers in directing therapies, with several clinical discovery studies underway and one validation clinical trial looking at the predictive value of treatment response to HER2 therapies also present (NCT02656589) [95].